Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts

Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.